Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.40 USD
Change Today -1.40 / -3.91%
Volume 862.9K
CEMP On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Snapshot

Open
$35.76
Previous Close
$35.80
Day High
$37.22
Day Low
$34.25
52 Week High
07/24/15 - $46.99
52 Week Low
09/22/14 - $9.61
Market Cap
1.5B
Average Volume 10 Days
923.6K
EPS TTM
$-1.78
Shares Outstanding
43.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEMPRA INC (CEMP)

cempra inc (CEMP) Related Businessweek News

No Related Businessweek News Found

cempra inc (CEMP) Details

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

55 Employees
Last Reported Date: 02/26/15
Founded in 2005

cempra inc (CEMP) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $475.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $325.0K
Chief Commercialization Officer and Executive...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

cempra inc (CEMP) Key Developments

FDA Grants Fast Track Designation to Cempra, Inc. for Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia

Cempra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for solithromycin intravenous (IV) and capsules for the treatment of community acquired bacterial pneumonia (CABP). Solithromycin is currently in Phase 3 development for the treatment of CABP and submission of a New Drug Application (NDA) is planned for 2016. Additional clinical studies with solithromycin include a Phase 3 trial in uncomplicated gonorrhea that is expected to complete patient enrollment by the end of 2015, a Phase 2 trial in chronic obstructive pulmonary disease (COPD), a Phase 2 trial in nonalcoholic steatohepatitis (NASH), and a Phase 1b trial in pediatric patients. The FDA has previously designated solithromycin IV and capsules for the treatment of CABP and solithromycin capsules for the treatment of gonorrhea as a Qualified Infectious Disease Product (QIDP). The QIDP designation will make solithromycin eligible to benefit from certain incentives as provided under the Generating Antibiotic Incentives Now (GAIN) program. These incentives include FDA priority review, eligibility for fast-track status and, if ultimately approved by the FDA, solithromycin would be eligible for an additional five-year extension of Hatch-Waxman new chemical entity exclusivity.

Cempra, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Cempra, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss attributable to common shareholders of $25.0 million, or $0.57 per basic and diluted share, compared to a net loss of $16.4 million, or $0.49 per basic and diluted share, for the same period in 2014. Loss from operations was $24.353 million against $15.906 million a year ago. For the six months, the company reported net loss attributable to common shareholders of $42.4 million, or $0.98 per basic and diluted share, compared to a net loss of $33.4 million, or $1.01 per basic and diluted share, for the six months ended June 30, 2014. Loss from operations was $41.158 million against $32.397 million a year ago.

Cempra, Inc. to Report Q2, 2015 Results on Jul 29, 2015

Cempra, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $34.40 USD -1.40

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies
 

Industry Analysis

CEMP

Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.5x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit www.cempra.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.